In his presentation at Ending Age-Related Diseases 2020, LEAF board member Javier Noris discussed the Longevity Impact Fund, the reasons why biotechnology funding has been lacking, the “valley of death” that must be crossed in order to fully fund early-stage research through the clinical trial process, and new ways in which venture capital can fund high-risk biotechnology ventures.
Javier Noris Presents the Longevity Impact Fund at EARD2020

Write a comment: